This month’s announcements on new products, tech partnerships, and more includes DiMe, Evonik, Advarra, Curebase, ObvioHealth, and other notable companies.
This month’s announcements on new products, tech partnerships, and more includes DiMe, Evonik, Advarra, Curebase, ObvioHealth, and other notable companies.
Virtual research organization has expanded its tech alliance with Dedalus Group to include global licensing of Dedalus’s technology. This new agreement grants ObvioHealth use of Dedalus’s data mining and analytics tools for their own research, and for that of its partners and sponsors.
This technology reportedly will enable access to analytics of ObvioHealth’s own multi-source healthcare data to inform better clinical trial design and recruitment as well as longitudinal disease and treatment trends. Partner sites and their providers will also be able to propose clinical trials to their patients, a key area of opportunity given a recent WRG Market Analysis indicating that only 3% of physicians and 5% of patients currently participate in clinical trials; the data also reportedly will help train AI-enabled digital and diagnostic instruments to provide deeper analysis of certain disease states.
Curebase has released an upgraded mobile app for clinical trial participants, intended to make the experience of participating in studies more convenient. The app, available on the Apple App Store and Google Play, reportedly delivers a flexible option to enable patient choice participation across studies.
“We’ve learned that patients want choice; patients can enjoy the convenience of an app-based experience with push-notifications, while also having the ability to receive SMS/email reminders and enter data on any other device through the web-app as well,” said Curebase founder and CEO Tom Lemberg. “If patients choose to opt for an app on their device(s), they can feel comforted knowing that they can pick up where they left off via the web-app if they lose their phone, are away from their device, or using public internet access.”
DiMe has introduced four comprehensive toolkits to help guide data producers, processors, and consumers to use the influx of data from the increased use of wearables and digital sensing products at scale.
“This opportunity powers the possibility of using high quality, high resolution flows of data to reimagine our approach to healthcare and research, leveraging more complete information to improve individual clinical decisions, decisions about the effectiveness of new medical products, and broader policy and public health decisions,” said DiMe CEO Jennifer Goldsack. “DiMe’s new Sensor Data Integrations Toolkits provide action-oriented resources to help data producers, processors, and consumers come together to create a sensor data ecosystem suitable for scale.”
Evonik’s Eudracap capsules, intended for clinical trials, are now globally available produced under IPEC-GMP. Eudracap enteric are functional, ready-to-fill capsules that help pharmaceutical companies bring complex oral drug products to market faster.
“We are happy to provide our unique Eudracap solution to meet the needs of customers with a growing number of sensitive molecules in their drug product portfolio,” said Bettina Hölzer, senior project manager for strategic marketing of oral drug delivery solutions.
The two companies have partnered in an effort to delivery a single, integrated solution with an intuitive interface that provides improved eCOA, ePRO, and eConsent technology. The combined offering is intended to be cost-accessible, fast to deploy, and easy for participants to use on their own mobile devices.
“It is encouraging and refreshing to see so many sponsors and CROs adopt patient-first technologies like eCOA, ePRO (patient reported outcomes) and eConsent, but too often they are frustrated by disjointed solutions that place a high burden on users and limit effectiveness,” said Steve Rosenberg, CEO of uMotif. “Together, uMotif and ClinOne are setting out to directly address these pain points with a seamless and comprehensive solution that trial participants actually want to use. In this way, we will add immediate value to increase data quality and reduce risk while improving convenience and comfort for everyone involved with the trial.”
Advarra has released an end-to-end Secure Document Exchange solution within its eRegulatory Management (eReg) system. Combined with recently released functionality in Advarra’s Longboat Platform, the technology is intended to allow sites and sponsors to build new efficiencies while using their own practice management systems for regulatory document management.
“We are committed to improving administrative workflows and creating efficiencies wherever possible; the implementation of Secure Document Exchange between eReg and sponsor systems is a welcome enhancement that aligns with these goals,” said Denise Snyder, associate dean for clinical research at Duke University and member of Advarra’s Site-Sponsor Consortium. “Giving our research teams the ability to leverage the eReg system we already use to share documents with sponsors will be a game-changer, particularly during study startup.”
The Atlas component of the company’s Reveal SingleCell app is designed to enable researchers to create a custom cell atlas by selectively combining an unlimited number of samples from multiple datasets for specific research objectives, explicitly saving them for collaboration, reuse, and regulatory filings.
Zachary Pitluk, vice president of life sciences at healthcare at Paradigm4, said, “Since its launch, Reveal SingleCell has been embraced by the single cell analysis community, with as many as 80m cells in play in some installations. Current customer installations are supporting thousands of queries per day with the present implementation. Importantly, the addition of the Precision Cell Atlas functionality should increase the supportable queries and drive projects forward at a much faster rate than is currently available.”
The TempTraq wireless, continuous temperature monitor is an FDA-cleared Class II medical device in the form of a soft, disposable patch. According to the manufacturer, the monitor can improve the way temperature is measured in the clinical environment and provide clinicians a quicker, easier, and more effective way to measure temperature.
In a recent study published in the journal Pediatric Blood and cancer shows how continuous temperature monitoring via a Bluetooth-enabled wearable patch can detect fever hours earlier than a conventional thermometer. Additionally, continuous temperature monitoring can help scientists view how a treatment affects body temperature in real time without relying on self-reporting from clinical trial patients.
